A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
Most Recent Events
- 19 Aug 2024 Planned number of patients changed from 40 to 30.
- 19 Aug 2024 Planned End Date changed from 30 Jun 2028 to 19 Aug 2029.
- 19 Aug 2024 Planned primary completion date changed from 30 Jun 2028 to 19 Aug 2029.